BioLargo, Inc.
BLGO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $3 | $3 | $4 |
| % Growth | -60.3% | -15.1% | -10.6% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $2 |
| Gross Profit | $0 | $1 | $1 | $2 |
| % Margin | 33.7% | 51.2% | 45.5% | 47.9% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $3 | $2 | $2 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $7 | $3 | $3 | $3 |
| Operating Income | -$6 | -$2 | -$2 | -$2 |
| % Margin | -584.7% | -64.9% | -57% | -44.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$6 | -$2 | -$2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$1 | -$1 | -$1 |
| % Margin | -587.4% | -42.9% | -35.3% | -27.7% |
| EPS | -0.02 | -0.004 | -0.004 | -0.003 |
| % Growth | -412.8% | -2.6% | -11.8% | – |
| EPS Diluted | -0.02 | -0.004 | -0.004 | -0.003 |
| Weighted Avg Shares Out | 309 | 303 | 301 | 301 |
| Weighted Avg Shares Out Dil | 309 | 303 | 301 | 301 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$2 | -$2 | -$2 |
| % Margin | -572.7% | -62% | -55% | -42.1% |